Telix Pharmaceuticals Limited is a commercial-stage radiopharmaceutical company focused on targeted theranostics for cancer. The company develops diagnostic imaging agents and therapeutic radioconjugates to treat prostate, kidney, and brain cancers. Its commercial products include Illuccix and Gozellix for prostate cancer imaging, and Pixclara for glioma imaging. The pipeline includes late-stage therapeutic candidates TLX591-Tx for prostate cancer, TLX250-Tx for kidney cancer, and TLX101-Tx for glioblastoma. Telix operates a vertically integrated manufacturing and distribution network through Telix Manufacturing Solutions (TMS) and RLS Radiopharmacies. The company serves markets in the United States, Europe, and Asia-Pacific, and has entered a strategic collaboration with Regeneron Pharmaceuticals to co-develop next-generation radiopharmaceutical therapies.

Summarised from the company's own disclosures, fiscal year ended Jun 2026

Industry Pharmaceuticals, Biotechnology & Life Sciences Homepage telixpharma.com
Sector Healthcare IR page ir.telixpharma.com
Tags
radiopharmaceuticals, theranostics, prostate cancer, kidney cancer, glioblastoma, pet imaging, radioconjugates, precision medicine, Illuccix, Gozellix, Pixclara, Zircaix, TLX591-Tx, TLX250-Tx, TLX101-Tx, TLX591-Px, TLX007-Px, TLX101-Px, TLX250-Px, BiPASS, Telix Manufacturing Solutions, RLS Radiopharmacies, Regeneron Pharmaceuticals
Press page —

Metrics

Valuation  
Market cap A$ 4.663B
Market cap (USD) $ 3.14B
P/E -55.77
PEG —
P/BV —
P/S 24.14
P/OCF -189.40
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE -51.5%
ROI -17.4%
ROIC -9.0%
Profit margin -73.2%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 105.9%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score -56.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Revenue 803.794M 524.438M 332.978M 108.913M 4.898M
Net profit -7.125M 33.426M 4.208M -104.079M -58.363M
Free cash flow -42.985M 19.222M 7.164M -77.831M -60.667M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Share price 7.49 15.4 — — —
Price performance 12m -0.51 — — — —

Filed figures

Figure Dec 2022 Dec 2023 Dec 2024 Dec 2025
Income detail
Research and development expense (AUD) 80.7M 129M 195M 171M
Reported Feb 24, 2025 Feb 24, 2025 Feb 24, 2025 Feb 20, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Appendix 3Y Maria Rivas Bull 0 Bear 0 Routine
Telix Capital Markets Day Presentation November 2026 Bull 0 Bear 0 Routine

Prompts

Telix Pharmaceuticals Limited (ticker TLX), listed in Australia.

Company History

Date Change Detail
Dec 31, 2025 Reporting currency Its US reports are in USD instead of AUD from this period. Earlier figures are shown in USD, converted at each period end's exchange rate.
Dec 31, 2023 Reporting currency Its AU reports are in USD instead of AUD from this period. Earlier figures are shown in USD, converted at each period end's exchange rate.

ETFs Holding Telix Pharmaceuticals Limited

ETF Weight in ETF Shares Market value As of
CORO 0.02% 23,044 $ 3.419M Nov 16, 2026
DFSI 0.02% 22,364 $ 208.649K Nov 12, 2026
DFIS 0.02% 98,614 $ 920.038K Nov 12, 2026
APIE 0.01% 8,699 $ 96.472K Aug 31, 2026
DFIC 0.01% 106,625 $ 994.778K Nov 12, 2026
DFAI 0.01% 111,918 $ 1.044M Nov 12, 2026
DFAX 0.00% 43,415 $ 405.049K Nov 12, 2026
IALT 0.00% 2,228 $ 330.548K Nov 16, 2026
AVSD 0.00% 60 $ 533.39 Nov 16, 2026
AVDS 0.00% 27 $ 240.02 Nov 16, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
TLX Common share — US nasdaq 10.97 USD 2026-09-30
TLX canonical Common share — AU asx 12.89 AUD 2026-10-26